Form 4 for RKDA Arcadia Biosciences, Inc.
Accepted 2022-08-03 00:00:00 ET · period of report 2022-08-01 · accession 0001209191-22-044269 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 2022-08-03 | 2022-08-01 | RKDA | Haley Pamela | CFO | P - Purchase | $0.7 | +700 | 5,088 | +16% | +$490.00 |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2022-08-01 | P | A | 700 | $0.7 | 5,088 | D | — | — | (F1) Reflects the purchase of 700 shares of the Issuer's common stock on 8/1/22 at a per share purchase price of $0.70 pursuant to participation in the Issuer's 2015 Employee Stock Purchase Plan ("ESPP"). This transaction is exempt from Rule 16b-3(c). In accordance with the ESPP, these shares were purchased at a price equal to 85% of the closing price of Issuer's common stock. (F2) The amount includes the 2015 Employee Stock Purchase Plan ("ESPP") purchases, for the purchase period of August 4, 2020 to August 1, 2022. These transactions were exempt from Rule 16b-3(c). In accordance with the ESPP, these shares were purchased at a price equal to 85% of the closing price of Issuer's Common Stock on the date of each respective purchase. |